Home Cart Sign in  
Chemical Structure| 1082949-67-4 Chemical Structure| 1082949-67-4

Structure of LY-2584702
CAS No.: 1082949-67-4

Chemical Structure| 1082949-67-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2584702 is an orally available inhibitor of p70S6K signaling and inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

Synonyms: LY-2584702 free base

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY-2584702

CAS No. :1082949-67-4
Formula : C21H19F4N7
M.W : 445.42
SMILES Code : CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3
Synonyms :
LY-2584702 free base
MDL No. :MFCD18633220
InChI Key :FYXRSVDHGLUMHB-UHFFFAOYSA-N
Pubchem ID :25118925

Safety of LY-2584702

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of LY-2584702

MAPK
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Hepa1-6 hepatocytes 1 μM 24 hours LY blocked the kinase activity of S6K1, thus reducing pS6 expression and significantly decreasing lipid accumulation in hepatocytes. PMC9431684
HEK293 cells 20 nM 3 hours Inhibition of p70S6K, reducing RPS6 phosphorylation at S235/236 and S240/244 PMC10485637
Human bone marrow mesenchymal stem cells (BMSC) 1 μM LY treatment inhibited the differentiation of BMSC into adipocytes, suggesting that LY may reduce adipogenesis by inhibiting S6K1 activity. PMC9431684

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6N mice High-fat diet-induced obese mouse model Oral gavage 25 mg/kg Every 12 hours for 12 weeks LY treatment significantly reduced body weight gain and fat accumulation in high-fat diet-induced obese mice and ameliorated hepatic steatosis and dyslipidemia. PMC9431684

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.25mL

0.45mL

0.22mL

11.23mL

2.25mL

1.12mL

22.45mL

4.49mL

2.25mL

References

 

Historical Records

Categories